Olivier Rascol on amantadine for patients wit...

What will Alzheimer’s disease diagnosis look like in 5–10 years? In this episode of In Conversation With…, Laura Hart is joined by the authors behind The Lancet Neurology Series on Future Directions in Alzheimer’s Disease and Related Disorders: Clifford Jack (Mayo Clinic), Charlo ...  Show more

For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet Neurology, Deputy Editor Laura Hart speaks with Professor Marjo van der Knaap (Amsterdam ...  Show more

Dr. Jason Crowell talks with Prof. Bastiaan Bloem about the latest developments in biomarkers and treatments for movement disorders, which have been described in numerous research papers from 2022. 

Read the related article in <a href= "https://www.thelancet.com/journal ...

Dr Alex Thompson, honorary consultant neurologist at Oxford University Hospitals NHS Trust, joins Sam for today's episode looking at motor neurone disease in PACES. We talk through the history, examination signs, differential diagnoses, investigations and management of this condi ...  Show more

We begin with a discussion about our article of the week which comes from The Lancet and is entitled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-c ...

Dr. Alison Christy talks with Dr. Tatjana Bremova-Ertl about the use of N-acetyl-L-leucine in pediatric and adult patients with GM2 gangliosidoses.

Read the related article in Ne ...